Tamoxifen: Ɔndastand yu Brest Kansa Ɔmon Tɛrapi

We yu yɛri di wɔd dɛm "brɛst cancer" frɔm yu dɔktɔ kin fil lɛk se di wɔl de fɔdɔm. Na kɔmplit nɔmal tin fɔ gɛt frayd ɛn wɔri, wit bɔku bɔku kwɛstyɔn dɛn bɔt tritmɛnt plan ɛn mɛrɛsin. Kwɛshɔn dɛn lɛk, "Dis mɛrɛsin sef?", "I go mek yu gɛt sayd ɛfɛkt?", "I rili wok?" i go mɔs bi se dɛn de swirl na yu maynd. Tide, wi go tɔk simpul ɛn opin wan bɔt Tamoxifen, we na wan mɛrɛsin we rili kɔmɔn ɛn impɔtant we dɛn kin yuz fɔ mɛn bɔdi kansa.

Wetin na Tamoxifen?

Fɔ tɔk am simpul wan, Tamoxifen na mɛrɛsin we dɛn kin yuz mɔ fɔ trit ɔmon riseptɔ-pɔzitiv brɔst kansa . Dis kayn brεst kεnsar de dip pan כmon dεm lεk εstrojen כ prכjεstεron fכ gro. Tamoxifen de kam insay tablɛt fɔm (Nolvadex®) ɔ likwid fɔm (Soltamox®).

Yu kin de wɔnda, "Wetin na di ɔmon riseptɔ-pɔzitiv brɔst kansa?" i strεt: sכm kεnsar sεl dεm na di bכdi nid כmon dεm – spεshal εstrojen εn/כ projεstεron – fכ fכl dεn gro εn spre, lεk aw plant nid wata εn nyutriεnt dεm. Tamoxifen de wok bay we i de blok di akshכn we εstrojen de du pan dεn kεnsar sεl dεm ya. Tink bɔt am lɛk we yu de ɔf di tap we de gi di plant tin fɔ it; if i nכ gεt εstrojen in signal, di kεnsar sεl dεm nכ kin gro כ mכltipl as ifektiv.

Apat frɔm dat, sɔntɛnde dɔktɔ dɛn kin gi Tamoxifen to pipul dɛn we gɛt ay risk fɔ gɛt bɔdi kansa (fɔ ɛgzampul, di wan dɛn we gɛt strɔng famili histri ɔ spɛshal jin muteshon lɛk BRCA) as fɔ mek dɛn nɔ gɛt am.

Udat dɛn kin gi di mɛrɛsin we dɛn kɔl Tamoxifen?

Dɛn nɔ kin gi tamoxifen fɔ ɛvri wan pɔsin we dɛn no se gɛt bɔdi kansa. Yu dɔktɔ go tek tɛm tink bɔt yu patikyula sityueshɔn, di kayn ɛn stej we yu gɛt kansa, ɛn ɔda tin dɛn we go mek yu gɛt wɛlbɔdi bifo i disayd if na di rayt tritmɛnt fɔ yu. Dɛn kin yuse am na dɛn kayn tin ya:

• Fɔ pipul dɛm we gɛt ay risk fɔ gɛt brɔst kansa (ɛgz., bikɔs ɔf famili histri ɔ BRCA jin muteshɔn) as prɛvɛntiv strateji.
• Afta ɔpreshɔn, kemotɛrapi, ɔ redyushɔn tɛrapi fɔ brɔst kansa we dɔn de, fɔ ridyus di chans fɔ mek di kansa kam bak (fɔ kam bak).
• Na pɔsin we dɔn gɛt kansa na wan bɔdi, fɔ mek i nɔ gɛt kansa na di ɔda bɔdi.
• Fɔ di fɔs stej kansa lɛk Ductal Carcinoma In Situ (DCIS), fɔ mek i nɔ go bifo to invasive kansa.

Di impɔtant tin na dat, di disayd fɔ tek Tamoxifen, ɛn fɔ aw lɔng, yu fɔ bi ɔltɛm we yu tɔk to yu wɛlbɔdi biznɛs pɔsin. Nɔ shem fɔ tɔk to dɛn bɔt ɛnitin we de mɔna yu ɔ kwɛstyɔn we yu gɛt.

Di Ki Bɛnifit dɛn we Tamoxifen Gɛt

Tamoxifen na mɛrɛsin we de sev layf fɔ bɔku bɔku uman dɛn ɔlsay na di wɔl fɔ lɔng lɔng tɛm. Di bɛnifit dɛn we i kin gɛt rili impɔtant:

• Ridyus di risk fɔ kam bak: I kin mek di risk fɔ mek yu gɛt bɔdi kansa bak afta di fɔs tritmɛnt bay 30% to 50%.
• I de protɛkt di ɔda bɔdi: pan di wan dɛn we gɛt kansa na wan bɔdi, i de ridyus di risk fɔ gɛt kansa na di ɔda bɔdi bay lɛk 50%.
• I de mek pɔsin nɔ gɛt kansa: Fɔ pipul dɛn we gɛt ay risk, i kin ridyus di ɔl risk fɔ gɛt bɔdi kansa bay lɛk 40%.
• I de mek di bon dɛn strɔng: I de ɛp fɔ mek yu nɔ gɛt ɔstioporosis (di bon dɛn we de tan), mɔ afta we yu dɔn menɔpauz.
• I de mek di kɔlɔstrel go dɔŋ: Tamoxifen kin ɛp fɔ mek di ‘bad’ kɔlɔstrel we de na di blɔd go dɔŋ.

Potεnshal Sayd Efεkt dεm we Tamoxifen Gεt

Lɛk ɛni mɛrɛsin, Tamoxifen kin gɛt sayd ɛfɛkt. E fayn fɔ mɛmba se nɔr to ɔlman kin gɛt dɛn, ɛn aw dɛn kin tranga kin difrɛn bad bad wan. Sɔm pipul dɛn nɔ kin gɛt wan, ɛn ɔda wan dɛn kin gɛt wan ɔ tu. We yu no bɔt di bad tin dɛn we kin apin to yu, dat kin ɛp yu fɔ kɔntrol dɛn fayn fayn wan.

I rili impɔtant fɔ mɛmba se siriɔs sayd ɛfɛkt dɛn nɔ kin apin so ɔltɛm . Bɔt fɔ no ɛn ripɔt kwik kwik wan ɛni sayn we de mɔna yu to yu dɔktɔ.

Ustɛm fɔ Kɔntakt Yu Dɔkta Wantɛm wantɛm

If yu de tek Tamoxifen, kɔntak yu dɔktɔ ɔ go to imejensi kia wantɛm wantɛm if yu gɛt:

• Chɛst pen ɔ i nɔ kin izi fɔ blo.
• Fiva.
• Di sayn dɛm fɔ strok (we yu nɔ de tɔk fayn, yu de si chenj, yu wik na wan say).
• Yu leg, yu anklɛ, ɔ yu fut kin swel wantɛm wantɛm (espɛshali if na wan say nɔmɔ).
• I de vɔmit bad bad wan ɔ we nɔ de chenj.
• Blɔd we nɔ kɔmɔn na di vagina.

Kwɛstyɔn dɛn we dɛn kin aks bɔku tɛm bɔt Tamoxifen

Yu tink se Tamoxifen na di sem tin wit kemotɛrapi?

Nɔ, dɛn na difrɛn kayn tritmɛnt. Tamoxifen na ɔmon tɛrapi we de blok di ifɛkt we ɛstrojen gɛt pan kansa sɛl dɛn. Kimotɛrapi de yuz drɔgs fɔ kil di sɛl dɛn we de sheb kwik kwik wan (ɔl tu di kansa ɛn sɔm sɛl dɛn we gɛt wɛlbɔdi). Bɔku tɛm dɛn kin wok togɛda bɔt dɛn kin gɛt difrɛn we dɛn fɔ du tin.

A kin tek Tamoxifen we a gɛt bɛlɛ?

Nɔto so i bi atɔl. If yu tek Tamoxifen we yu gɛt bɛlɛ, i kin mek yu bɔn bad bad wan. If yu de tek Tamoxifen, yu fɔ avɔyd fɔ gɛt bɛlɛ. Tɔk bɔt di we dɛn we pɔsin kin abop pan, we nɔ gɛt ɔmon fɔ kɔntrol bɔn pikin wit yu dɔktɔ.

Fɔd dɛn de we a fɔ avɔyd we a de tek Tamoxifen?

Yɛs, grep ɛn tanjɛrin kin ambɔg aw yu bɔdi de prosɛs Tamoxifen, we kin mek i nɔ wok fayn. Dɛn kin advays bak fɔ stɔp ɔ nɔ drink rɔm.

Aw lɔng a nid fɔ tek Tamoxifen?

di tεm we yu de tek kin difrεn dipכnt pan yu spεsifi k situeshכn (εgz., prεvεntiv yus vs. tritmεnt afta kεnsar). Tipikli, e kin tek fכ 5 ia, bכt sכmtεm i kin tek lכng pas dat. Yu dɔktɔ go disayd ɔmɔs tɛm fɔ yu.

Ki tin dɛn we dɛn kin tek fɔ tek

• Tamoxifen na wan ɔmon tɛrapi we rili fayn fɔ ɔmon riseptɔ-pɔzitiv brɔst kansa.
• I de ridyus di risk fɔ gɛt kansa bak ɛn divɛlɔp pan pipul dɛn we gɛt ay risk.
• Pan ɔl we sayd ɛfɛkt kin apin, bɔku pan dɛn kin ebul fɔ kɔntrol, ɛn siriɔs wan dɛn nɔ kin apin so ɔltɛm.
• Ɔltɛm tek Tamoxifen jɔs lɛk aw yu dɔktɔ tɛl yu fɔ di ful tɛm.
• Opin kɔmyunikeshɔn wit yu wɛlbɔdi tim rili impɔtant. Tɔk bɔt ɛni wɔri ɔ sayn wae yu gɛt.

Tamoxifen kin bi pawaful tin fɔ mɛn di bɔdi kansa. We yu ɔndastand di wok we i de du, di bɛnifit dɛn we i gɛt, ɛn di sayd ɛfɛkt dɛn we i kin gɛt, dat kin mek yu ebul fɔ tek pat tranga wan pan yu tritmɛnt joyn.

Disklɛmayshɔn: Dis atikul de gi jenɛral infɔmeshɔn bɔt dis sik ɛn i nɔ fɔ tek ples fɔ di advays we yu dɔktɔ gi yu. Ɔltɛm, go to pɔsin we sabi bɔt wɛlbɔdi biznɛs.

Kwɛstyɔn dɛn we dɛn kin Aks Bɔku tɛm (FAQ) .